Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for MCUJF. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: MCUJF is a Sell candidate.
MCUJF stock price ended at $0.79 on 木曜日, after dropping 13.19%
On the latest trading day Feb 12, 2026, the stock price of MCUJF fell by 13.19%, dropping from $0.79 to $0.79. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.79 and a high of $0.79. On the latest trading day, the trading volume for MCUJF decreased by 5.1K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.5K shares were traded, with a market value of approximately --.